JW Therapeutics and 2seventy Bio Ink Exclusive Deal for CAR-T Cell Therapy in Greater China
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has announced an exclusive collaboration...
InventisBio’s KRAS G12C Inhibitor Garsorasib NDA Accepted for Review by China’s NMPA
InventisBio (Shanghai) Co., Ltd (SHA: 688382), a China-based pharmaceutical company, has announced that the New...
Frontage Laboratories Expands European Footprint with Acquisition of Accelera’s DMPK Businesses
Frontage Laboratories Inc., (HKG: 1521), a Contract Research Organization (CRO) with operations in Pennsylvania, Suzhou,...
AstraZeneca and Sanofi’s RSV Prevention Drug Beyfortus Approved by China’s NMPA
AstraZeneca (AZ, NASDAQ: AZN) and Sanofi (NASDAQ: SNY), co-development partners in the pharmaceutical industry, have...
China Medical System Expands into Southeast Asia with Singapore Manufacturing Plant Lease
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that its joint venture, PharmaGend...
Ascletis Pharma’s ASC41 Shows Promising Results in Phase II NASH Study
Ascletis Pharma Inc. (HKG: 1672), a Chinese pharmaceutical company, has announced positive interim results from...
Shanghai Junshi Biosciences’ Toripalimab Gains NMPA Approval for NSCLC Perioperative Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Roche’s Phesgo and Faricimab Receive NMPA Approvals for Breast Cancer and nAM
The National Medical Products Administration (NMPA) has granted separate approvals for two distinct drugs from...
WuXi XDC and IntoCell Enter MOU to Advance Toxin Linker Technology and CRDMO Services
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
BeiGene’s Tislelizumab Secures 12th Indication Approval in China for HCC First-Line Treatment
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received approval...
BMS’ Augtyro Receives EMA Review for Advanced Lung Cancer and Solid Tumors Treatments
The European Medicines Agency (EMA) has accepted for review a filing submitted by Bristol Myers...
Allorion Therapeutics Strikes Deal with AstraZeneca for EGFR L858R Inhibitor Development and Commercialization
Allorion Therapeutics, a China-based biopharmaceutical company, has announced an exclusive option and global licensing agreement...
Orient Gene Biotech to Acquire Hangzhou Laihe Biotech, Expanding POCT and AI in Healthcare
Zhejiang Orient Gene Biotech Co., Ltd, a leading biotech company in China, is poised to...
Shanghai Teogen Life Technology and China National Medical Device Form Strategic Partnership
Shanghai Teogen Life Technology Co., Ltd, a Chinese-based company, has announced a strategic partnership with...
Shanghai Pharmaceuticals and Sanofi Broaden Collaboration to Include Nationwide Disease Management
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) , a leading pharmaceutical company based in China,...
Servier Faces $475 Million Penalty Over Banned Antidiabetic Drug Mediator in France
French pharmaceutical company Servier has been ordered by a French court to pay €430.6 million...
J&J Shareholders Cleared to Sue Over Hidden Asbestos Risks in Talc Products
A US federal court has granted permission for certain Johnson & Johnson (J&J; NYSE: JNJ)...
China’s CDE Releases Guidelines for CGT Clinical Trials Communication
The Center for Drug Evaluation (CDE) in China has released the “Technical Guiding Principles for...
China’s NHC Unveils Plan to Conserve Drug Resources and Reduce Waste
The National Health Commission (NHC) of China, in collaboration with four other bureaus, has released...
China’s NHC Unveils Guidelines to Fortify County-Level Medical Communities
The National Health Commission (NHC) of China, in conjunction with nine other ministries, has issued...